Isareli-Based Innocan (INNO:CSE) Distribution and Manufacturing Agreements, In Both Europe and USA, Point To Commercialization Of Clinically Proven CBD Products In 2021

2020 has been a disappointing one for the once euphoric cannabis  industry thanks to the fallout of over-hyped and over-financed companies  that failed to deliver on a fraction of their promises. The  year 2000 saw the exact same thing happen to "dot-com" companies that  failed in even more spectacular fashion.  Many investors swore off  internet stocks forever.  The smart ones waited to see which companies  were real ... and the rest was history as we saw the birth and growth of  internet companies that delivered real value, products and customers. The  same is about to happen in the Cannabis space.  With the market  estimated to hit $70 Billion over the next few years, there is very  little doubt that winners will be created out of companies delivering  real businesses Enter Innocan Pharma  Corporation (INNO:CSE) (IP4: FSE) and it's incredible team of  accomplished scientists led by CEO Iris Bincovich.   As a  Cannabis investor, why limit yourself to a Company with just one  specialty, when InnoCan offers you exposure to both the exploding world  of cannabis pharma, as well as, a portfolio of patent-pending and launch  ready consumer health products, the latter of which have already  announced distribution and manufacturing agreements throughout Europe  and the United States, If you believe in  the future of the cannabis and companies delivering real, value-add CBD  products, then watch this interview with Innocan CEO, Iris Bincovich.